企業プロフィール
Legend Biotech Corporation 株価・ニュース・カタリスト
- ティッカー:
- LEGN
- 取引所:
- NASDAQ
- セクター:
- CAR-T Therapy, TCR-T Therapy, Antibody Drugs, ADCs, Biopharma
- 所在地:
- China with major global operations and listed in the U
株価パフォーマンス
20.65 USD (+1.37%)
終値
最終更新: 2026年8月17日
6.74B USD
時価総額
株価変動の要因
As of Aug 17, 2026, LEGN closed up 1.37% at $20.65. No new same-company headline was identified in the current news window.
企業概要
Global Cell Therapy Company
Legend Biotech develops and commercializes cell therapies for cancer and other serious diseases.
CARVYKTI
CARVYKTI, or ciltacabtagene autoleucel, is a one-time BCMA-directed CAR T-cell therapy for multiple myeloma developed and commercialized with Johnson & Johnson.
Global Manufacturing and Access
Legend supports CARVYKTI across 18 markets through expanding manufacturing capacity, treatment-center certification, and partner-led commercialization.
CARVYKTI Clinical Expansion
The cilta-cel franchise is being developed across earlier lines of multiple myeloma treatment to broaden access beyond heavily pretreated disease.
Earlier Cell Therapy Pipeline
The company is advancing additional cell therapies beyond BCMA, including programs for hematologic malignancies and solid tumors.
今後のカタリスト
- Legend Biotech’s catalysts are Carvykti sales growth, label-expansion opportunities, and further commercial execution in multiple myeloma. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。